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Abstract
Background: Several inflammation biomarkers have been implicated in the pathogenesis 
and prognosis of acute coronary syndromes. However, the prognostic role of the neutrophil-
-lymphocyte white cell interactive response to myocardial injury in predicting short- and long-
-term mortality after ST elevation myocardial infarction (STEMI) remains poorly defined.
Methods: We evaluated 250 consecutive STEMI patients presenting acutely for revasculari-
zation to our tertiary care center over 1 year. Patients with acute sepsis, trauma, recent surgery, 
autoimmune diseases, or underlying malignancy were excluded. Data gathered included de-
mographics, clinical presentation, leukocyte markers, electrocardiograms, evaluations, therapy, 
major adverse cardiac events, and all-cause mortality.
Results: Mean age was 62 ± 15 years, 70.4% of subjects were males while majority (49.4%) 
were Caucasians. Mean duration of follow-up was 571 ± 291 days (median 730 days). Uni-
variate analysis of several inflammatory biomarkers including C-reactive protein, revealed white  
cell count (OR = 1.09, p < 0.001) and neutrophil to lymphocyte ratio (NLR) (OR = 1.05,  
p = 0.011) as predictors of short- and long-term mortality; but not mean neutrophil count  
(OR = 1.04, p = 0.055) or lymphocyte count alone (OR = 0.96, p = 0.551). Multivariate ana-
lysis using backward stepwise regression revealed NLR (OR = 2.64, p = 0.026), female gender  
(OR = 5.35, p < 0.001), cerebrovascular accident history (OR = 3.36, p = 0.023), low glomerular 
filtration rate (OR = 0.98, p = 0.012) and cardiac arrest on admission (OR = 17.43, p < 0.001)  
as robust independent predictors of long-term mortality. NLR was divided into two sub-groups based 
on an optimal cut off value of 7.4. This provided the best discriminatory cut off point for predicting 
adverse mortality outcome. Both short-term (≤ 30 days) and long-term (≤ 2 years) mortality were 
predicted with Kaplan-Meier survival curve separation best stratified by a NLR cut off value of 7.4.
Conclusions: NLR based on an optimal cut off value of 7.4, was an excellent predictor of 
short- and long-term survival in patients with revascularized STEMI and warrants larger 
scale multi-center prospective evaluation, as a prognostic indicator. NLR offers improved 
prognostic capacity when combined with conventional clinical scoring systems, such as the 
Thrombolysis In Myocardial Infarction risk score. (Cardiol J 2014; 21, 5: 500–508)
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Introduction
Several researchers have shown an associa-
tion between various biomarkers of inflammation 
and pathophysiology of acute coronary syndromes 
(ACS) [1, 2]. Recently, multiple studies have shown 
that inflammatory biomarkers, e.g. white cell count 
and neutrophil to lymphocyte ratio (NLR), may 
have prognostic value in stable coronary artery 
disease (CAD), as well as in ACS [3, 4]. NLR is 
a surrogate marker for the combined effects of the 
innate immune response (substantially mediated 
by neutrophils), and the subsequent adaptive im-
mune response (substantially mediated by lympho - 
cytes). NLR may also reflect the myocardial 
remodeling responses after reperfusion injury 
[5–7]. Nevertheless, the role of NLR in predicting 
short- and long-term mortality after ST-segment 
elevation myocardial infarction (STEMI), treated 
with primary percutaneous coronary intervention 
(PCI) in the drug eluting stent era remains unde-
fined. Our study aimed to determine if NLR as an 
all-cause mortality outcome predictor, could be 
utilized alone, and in combination with current 
standardized cardiac risk score models, to improve 
the prediction of subsequent short- and long-term 
all-cause mortality.
Methods
Two hundred and seventy-eight consecutive 
patients presenting from January 2007 to January 
2008 with a diagnosis of STEMI based on elec-
trocardiographic (ECG) criteria were studied and 
followed until December 2010. Data prospectively 
collected in an ACS outcomes database were then 
retrospectively analyzed. Myocardial infarction 
(MI) was diagnosed by symptoms of ischemia 
and elevation in cardiac biomarkers, as defined by 
the Joint European Society of Cardiology and the 
American College of Cardiology [8, 9]. STEMI 
was defined as ST segment elevations measuring 
0.2 mV in leads V1 to V3 or 0.1 mV in all other 
leads with the above-mentioned changes present 
in at least two contiguous leads. Twelve lead ECGs 
were obtained at 25 mm/s paper speed, and 10 mV 
gain. Analysis of the first presenting ECG inclu-
ded: heart rate (HR), PR interval, QRS duration, 
corrected QT interval, QRS axis and T-wave axis.
Exclusion criteria
Out of the cohort of 278 patients, 11 patients 
were excluded due to presence of left bundle 
branch block or atrial fibrillation on the presen-
ting ECG. Five patients had a diagnosis of cancer; 
4 patients had underlying sepsis on presentation 
while 2 patients had recently undergone cardiac 
surgery. In 6 patients a complete blood count was 
not available leaving 250 patients for analysis.
Data collected
At presentation 12 lead ECG, complete blood 
count, metabolic panel, radiographic investigations, 
and echocardiographic data were obtained. All pa-
tients underwent emergent coronary angiography, 
and based on angiographic and clinical findings 
were treated with percutaneous coronary revascu-
larization or urgent coronary artery bypass grafting 
according to contemporaneous guidelines. Patients 
underwent concurrent anticoagulant therapy for 
PCI with unfractionated heparin/low molecular 
weight heparin and peri-procedural intravenous 
glycoprotein IIb/IIIa inhibitors, or bivalirudin (ma-
jority of cases). After coronary stent placement, 
patients received adjunctive dual antiplatelet 
therapy with aspirin and a thienopyridine anta-
gonist (mostly clopidogrel). Clinical information 
abstracted included systemic hypertension, diabe-
tes mellitus (DM), body mass index (BMI), prior 
MI, prior congestive heart failure (CHF), prior 
coronary revascularization, smoking status and 
relevant family history. Thrombolysis In Myocar-
dial Infarction (TIMI) study group definitions for 
current smoking and family history were utilized 
[10]. Congestive heart failure was defined as eje-
ction fraction (EF) less than 35%, elevated B-type 
natriuretic peptide (BNP) and/or evidence of fluid 
overload on chest radiograph. TIMI grade flow was 
measured as 0 = no perfusion, 1 = penetration 
without perfusion, 2 = partial reperfusion and 
3 = complete reperfusion [11].
Blood sampling
Blood sampling was performed within 24 h of 
STEMI presentation. A complete blood count with 
6-part differential was obtained with an automated 
Sysmex XE 5000 Hematology System (Sysmex 
America Inc., Mundelein, IL, USA). Cardiac bio-
markers including BNP and troponin I levels using 
an Advia Centaur XP Immunoassay (Siemens AG, 
Erlangen, Germany). Renal function, electrolytes 
and fasting lipid panel were measured using Advia 
1800 Clinical Chemistry systems (Siemens AG, 
Erlangen, Germany).
Outcome analysis
The primary endpoint used for the analysis 
was all cause mortality at the end of 2 years. Ma-
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jor adverse cardiovascular events (MACE) data 
including cardiovascular death, CHF, recurrent 
MI, and cardiac arrest were assessed at 30 days, 
6 months and 2 years. Mortality data during the 
index admission were obtained from hospital re-
cords. Subsequent 6 months and 2-year mortality 
data were obtained either from our hospital, or 
California Department of Public Health and Social 
Security Death Index records. Thrombolysis In 
Myocardial Infarction (TIMI-STEMI), Mayo Clinic 
Risk Score (MCRS) Global Registry of Acute Coro-
nary Events (GRACE) scores were also calculated 
for all subjects [10, 12, 13].
This study was approved by the institutional 
review board of Community Regional Medical 
Centers.
Statistical analysis
Statistical analysis was performed using SPSS 
Software (PASW for Windows, Rel. 18.0.0. 2009; 
SPSS Inc., Chicago, IL, USA). Continuous variables 
were summarized as mean ± standard deviation 
(SD) and comparisons between continuous va-
riables utilized the Student’s t-test. Categorical 
variables were summarized as percentages of the 
group total and comparisons between groups were 
analyzed using either Fisher exact test or c2 where 
appropriate. NLR was utilized as both a continuous 
and categorical variable, based on relative risk of 
mortality. Assessment of the bivariate relationship 
between mortality and each risk factor was perfor-
med using data from 250 patients. Variables identi-
fied as significant (p value < 0.1) during univariate 
analysis were then fitted in a logistic regression 
model by a backward elimination method. This ad-
justed for confounders and enabled determination 
of variables of interest associated with increased 
risk of mortality or major cardiovascular adverse 
outcomes. Differences in survival curves obtained 
using Kaplan-Meier analysis were compared using 
the log-rank test. Receiver operating curves (ROC) 
were constructed to obtain area under the curve 
(AUC), and to predict cut off values of NLR that 
could be used to predict mortality. Statistical sig-
nificance was accepted at p value < 0.05.
Results
Patient demographics, relevant medical histo-
ry, medications, laboratory findings, ECG data and 
treatments received are summarized in Table 1. 
Mean age was 62 ± 15 years, 70.4% of subjects 
were males while majority (49.4%) were Cau-
casians. Mean duration of follow-up was 571 ± 
± 291 days (median 730 days) and mean NLR was 
6.60 ± 7.8. Age (r = 0.198, n = 250, p = 0.002) and 
BNP level (r = 0.208, n = 127, p = 0.019) were po-
sitively correlated with NLR. Patients with higher 
NLR were more likely to be: older (p = 0.002), 
have CHF on presentation (p = 0.003); have eleva-
ted white cell count (p < 0.001); prolonged QRS 
duration (p = 0.040) and less likely to undergo 
PCI (p < 0.001). Standardized risk assessment 
scores like (TIMI-STEMI, MCRS and GRACE) 
were correspondingly elevated in patients with 
higher NLR values.
Predictive value of NLR
NLR was divided into two sub-groups based 
on optimal cut off value of 7.4, which provided 
the highest predictive power for mortality. NLR 
values of ≥ 7.4 demonstrated a sensitivity of 47.5% 
(95% CI 34.3–60.9%), specificity of 81.2% (95% 
CI 74.9–86.4%), and positive likelihood ratio of 
2.52 (95% CI 1.69–3.75) for mortality. ROC curves 
were constructed to assess the predictive value of 
NLR. To predict long-term mortality using NLR 
prediction ROC was performed to obtain AUC with 
C-statistic of 0.73. In order to improve the predic-
tive power of NLR in point of care scenarios, the 
NLR was combined with standardized ‘TIMI  risk 
score for STEMI’ variables. The predictive power 
was significantly improved when NLR was added 
to TIMI score clinical variables by assigning one 
point for NLR ≥ 7.4. Using this approach, the ROC 
AUC mortality prediction improved significantly to 
a C-statistic of 0.80, p < 0.001 (Fig. 1).
Outcomes
Mortality outcomes stratified by NLR cut off 
value of 7.4, at 3 time intervals  (in-hospital and 
up to 30 days post STEMI, 30 days to 6 months, 
6 months to £ 2 years) are shown in Figure 2. 
Compared to NLR < 7.4, patients with NLR ≥ 7.4 
had significantly higher mortality at all 3 follow-
-up time points: immediate hospitalization period, 
short-term and long-term. In the first 30 days after 
hospitalization, a total number of 41 deaths were 
observed, while a total number of 59 deaths were 
observed at the end of 2 years. The prediction of 
mortality at these 3 time points is of considerable 
clinical significance, due to the varying spectrum 
of modifiable risk factors at differing post STEMI 
time points. Table 2 outlines the MACE endpoints 
measured during index hospitalization and up to 
2 years of follow-up. The achievement of post-
-procedural TIMI grade 3 flow after PCI, did not 
differ significantly between patients with NLR 
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< 7.4, as compared to patients with NLR ≥ 7.4. 
NLR was also not significantly different between 
patients who achieved TIMI 0 flow compared to 
TIMI grade 2 or 3 flow after PCI.
Regression analysis
Using all-cause mortality as the primary outco-
me, univariate analysis was performed to determine 
which variables predicted mortality. Female gender, 
Hispanic race, age, BMI, smoking status, CHF hi-
story, cerebrovascular accident history, Killip CHF 
class on admission, high white cell count, low he-
moglobin, elevated BNP, low glomerular filtration 
rate (GFR) and cardiac arrest on presentation were 
all associated with elevated mortality risk (Table 3). 
When these variables were included in a multivaria-
te model using backward stepwise regression, NLR 
(OR = 2.64, p = 0.026), female gender (OR = 5.35, 
Table 1. Patient characteristics including demographics, medical history, medications, laboratory/elec-
trocardiography variables, anticoagulant therapy, reperfusion modality, and clinical risk scores strati-
fied by neutrophil to lymphocyte ratio cut off value of 7.4.
All  
(n = 250)
NLR < 7.4 × 109/L  
(n = 186)
NLR ≥ 7.4 × 109/L  
(n = 64)
P
Demographics
Age 62 ± 15 60 ± 14 67 ± 15 0.002
Gender (male) 176 (70.4%) 132 (71%) 44 (68.8%) 0.737
Race (Caucasian) 123 (49.4%) 88 (47.6%) 35 (54.7%) 0.368
Medical history
Smoking 114 (45.6%) 82 (44.1%) 32 (50%) 0.413
Diabetes 68 (27.4%) 52 (28.3%) 15 (25%) 0.614
Hypertension 179 (71.9%) 130 (70.3%) 49 (76.6%) 0.334
Congestive heart failure 70 (28%) 43 (23.1%) 27 (42.2%) 0.003
Atrial fibrillation 47 (18.9%) 34 (18.4%) 13 (20.3%) 0.733
Renal disease 26 (10.4%) 17 (9.1%) 9 (14.1%) 0.266
Medications
Aspirin use 83 (33.6%) 61 (33.2%) 22 (34.9%) 0.798
Beta-blocker use 79 (32.1%) 62 (33.9%) 17 (27%) 0.312
Statin use 83 (33.6%) 61 (33.2%) 22 (34.9%) 0.798
Angiotensin converting enzyme inhibitor use 92 (37.2%) 69 (37.5%) 23 (36.5%) 0.888
Presenting laboratory findings
Troponin on admission 29.59 ± 122 19.27 ± 76.39 57.69 ± 201.22 0.148
B-type natriuretic peptide 946 ± 1314 862 ± 1336 1130 ± 1263 0.288
White cell count 11.9 ± 6.1 11.08 ± 5.45 14.68 ± 7.48 < 0.001
Neutrophil count 8.7 ± 6.65 7.43 ± 6.30 12.41 ± 6.28 < 0.001
Lymphocyte count 2.26 ± 2.29 2.69 ± 2.49 0.98 ± 0.52 < 0.001
Hematocrit 40.8 ± 6.4 41.84 ± 5.60 37.84 ± 7.84 0.001
Electrocardiogram changes
Heart rate 83.66 ± 26.47 82.04 ± 24.4 88.78 ± 31.77 0.080
QRS duration 96.63 ± 24.67 94.53 ± 22.61 102.83 ± 29.74 0.044
Corrected QT interval 426 ± 39.67 425.4 ± 38.86 427.9 ± 43.14 0.666
ST segment resolution 168 (67.5%) 131 (70.8%) 37 (57.8%) 0.056
Treatment
Heparin (unfractionated) 60 (24.2%) 43 (23.4%) 17 (26.6%) 0.607
Low molecular weight heparin 40 (16.1%) 31 (16.8%) 9 (14.1%) 0.602
Percutaneous coronary intervention 157 (63.1%) 128 (69.2%) 29 (45.3%) 0.001
Coronary artery bypass grafting 34 (13.7%) 26 (14%) 8 (12.7%) 0.798
Risk scores for mortality
TIMI-STEMI 4.55 ± 2.87 4.16 ± 2.79 5.7 ± 2.75 < 0.001
Mayo Clinic Risk Score 8.25 ± 7.45 7.28 ± 6.42 11.38 ± 9.38 < 0.001
Global Registry of Acute Coronary Events© 125.8 ± 45.66 117.27 ± 42.68 150.78 ± 45.09 < 0.001
TIMI-STEMI — Thrombolysis in Myocardial Infarction-ST elevation myocardial infarction
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p < 0.001), cerebrovascular accident history 
(OR = 3.36, p = 0.023), low GFR (OR = 0.98, 
p = 0.012), and cardiac arrest on admission 
(OR = 17.43, p < 0.001) remained as independent 
predictors of long-term mortality as illustrated by 
the Forest plot (Fig. 3).
Survival analysis
Kaplan-Meier survival analysis was perfor-
med to measure all-cause mortality and survival 
free from systolic heart failure, stratified by NLR. 
Patients with NLR < 7.4 had higher survival 
compared to patients whose NLR was ≥ 7.4 du-
ring short-term follow-up of 30 days (Fig. 4A) and 
long-term follow-up of 2 years (Fig. 4B). NLR was 
also found to be a strong predictor of survival free 
from systolic heart failure (EF < 35%) as shown 
in Figure 4C.
Discussion
This study has demonstrated that in patients 
presenting for primary PCI revascularization with 
STEMI, an elevated NLR (based on an optimum 
Table 2. Major adverse cardiac event (MACE) 
end point frequencies up to 2-year follow-up.
MACE endpoints at 2 years All patients
Recurrent myocardial infarction 28 (11.2%)
Cardiac death 34 (13.6%)
Congestive heart failure 87 (34.8%)
Cerebrovascular accident 6 (2.4%)
Repeat coronary artery bypass graft 4 (1.6%)
Repeat percutaneous coronary  
intervention
5 (2%)
Figure 1. A. Receiver operating characteristic (ROC), area under the curve (AUC) analysis of neutrophil to lympho-
cyte ratio (NLR) alone in prediction of post-ST elevation myocardial infarction (STEMI) revascularization mortality; 
B. Significant improvement in predictive power of Thrombolysis in Myocardial Infarction-STEMI risk score variables 
by addition of NLR variable: c-statistic AUC improvement from 0.73 to 0.80 (p < 0.001).
Figure 2. Stratification of all-cause mortality based on 
neutrophil to lymphocyte ratio (NLR) cut off value of 7.4 
into 3 time periods: in-hospital and up to 30 days, 30 days 
to 6 months, and 6 months to £ 2 years mortality rates.
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derived cut off value > 7.4) is independently asso-
ciated with higher all-cause mortality and higher 
MACE rates at both short-term (£ 30 days), and 
long-term (≤ 2 years) follow-up. Rapid separation of 
Kaplan-Meier survival curves was observed within 
1-week post-STEMI PCI. An elevated NLR reflects 
both neutrophilia and relative lymphopenia. Seve-
ral studies have examined the role of neutrophils 
and lymphocytes in modulating the inflammatory 
response to myocardial injury [14–16]. Neutrophils 
are speculated to mediate increased plaque rupture 
and thrombosis by secreting proteolytic enzymes 
causing vascular damage, activation of coagulation 
pathways, micro vascular plugging and myocyte 
necrosis mediated by secretion of pro-inflammatory 
cytokines [1, 17]. Activated leukocytes may also 
modulate the electrical activity of the myocardium 
(and therefore arrhythmogenesis), by release of 
oxygen free radicals [18]. Leukocyte count has 
an interplay with other known CAD risk factors, 
such that it enhances the diagnostic capacity of 
conventional risk factors in predicting CAD [19]. 
Physiological stress and the subsequent activation 
of the neurohormonal system during STEMI leads 
to cortisol release, which in turn mediates lym-
phopenia through apoptosis [20]. Atherosclerosis 
and plaque rupture leading to ACS is an inflamma-
tory process mediated by the complex interplay 
Table 3. Univariate predictors of long-term mortality following revascularized ST elevation myocardial 
infarction.
Variable Mortality in 1 year (n = 59/250)
95% confidence interval P
Gender: male = reference 3.95 (2.15–7.25) < 0.001
Race: Caucasian = reference 3.6 (1.32–9.8) 0.012
Age 1.06 (1.04–1.08) < 0.001
Body mass index 0.90 (0.85–0.95) < 0.001
Diabetes type 2 1.30 (0.69–2.44) 0.416
Smoker 2.87 (1.52–5.42) 0.001
Hypertension 1.32 (0.67–2.59) 0.442
Hyperlipidemia 1.45 (0.81–2.60) 0.213
Congestive heart failure 3.43 (1.86–6.31) < 0.001
Atrial fibrillation 1.17 (0.57–2.44) 0.667
Previous myocardial infarction 1.32 (0.72–2.41) 0.369
Cerebrovascular accident 4.10 (1.86–9.0) < 0.001
Killip (Class 1 = reference) 7.46 (2.85–19.52) < 0.001
Troponin at admit 1.00 (0.99–1.00) 0.644
White cell count 1.09 (1.04–1.1) < 0.001
Neutrophil count 1.04 (0.99–1.09) 0.055
Lymphocyte count 0.96 (0.83–1.10) 0.551
Neutrophil to lymphocyte ratio 1.05 (1.01–1.08) 0.011
Anemia (hematocrit < 36) 5.61 (2.34–13.43) < 0.001
Glomerular filtration rate 0.98 (0.97–0.99) < 0.001
B-type natriuretic peptide 1.01 (1.00–1.01) 0.003
Left ventricular hypertrophy 1.19 (0.57–2.50) 0.646
Heart rate 1.09 (0.99–1.02) 0.086
PR interval 1.00 (0.96–1.00) 0.939
QRS duration 1.01 (0.99–1.02) 0.081
Corrected QT Interval 1.00 (0.996–1.01) 0.392
T wave changes 2.81 (1.20–6.56) 0.017
ST segment elevation 0.64 (0.35–1.16) 0.139
Cardiac arrest on admit 14.83 (7.30–30.12) < 0.001
TIMI grade 3 flow after PCI 1.17 (0.59–2.32) 0.645
MVD (≥ 2 vessel involved) 2.94 (1.23–7.03) 0.015 
PCI — percutaneous coronary intervention; TIMI — Thrombolysis in Myocardial Infarction MVD — multivessel disease
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Figure 4. Kaplan-Meier survival curve analysis of all-cause mortality for short-term (A), long-term (B) end points stra-
tified by neutrophil to lymphocyte ratio (NLR) cut off value of 7.4. Kaplan-Meier survival curve analysis of survival free 
of heart failure (C) stratified by NLR cut off value of 7.4.
Figure 3. Multivariate analysis of long-term mortality risk factors; *p < 0.05.
between the innate neutrophil mediated reactive 
immune responses, and subsequent lymphocyte 
mediated adaptive immune responses [5–7]. Thus, 
NLR may act as a combined surrogate marker 
for both the reactive and adaptive components of 
the inflammatory response that result in plaque 
rupture, ischemic myocardial damage, adverse 
ventricular remodeling, and consequent left ven-
tricular dysfunction.
Older age is a major predictor of adverse 
outcome in ACS. Age > 70 years has remained 
a major independent predictor of in-hospital car-
diovascular mortality in many STEMI prognosis 
studies [21]. Similar to our cohort where NLR > 7.4 
was independently associated with systolic heart 
failure, studies have shown that increased neu-
trophil count has been reliably associated with 
increased MI size and decreased left ventricular 
function [22]. Evidence of CHF with elevated 
BNP levels is associated with poor prognosis 
due to increased myocardial damage [23]. This is 
the proposed physiologic basis for the observed 
correlation between increased NLR, older age, 
increased BNP levels, and diminished long-term 
survival. Consistent with this, we also observed 
that prolonged QRS duration was associated with 
elevated NLR values, and diminished survival in 
our study. A post-hoc analysis of the Efficacy of 
Vasopressin Antagonism in Heart Failure Outcome 
Study with Tolvaptan (EVEREST) showed similar 
findings, where lymphopenia was associated with 
widened QRS duration and older age (both markers 
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of worse prognosis) [24]. Prolonged QRS reflects 
more extensive myocardial damage, and the ad-
verse ventricular remodeling that accompanies 
this (vide supra).
We tested the predictive value of NLR both in-
dependently and in conjunction with well-validated 
standardized MI risk scores. We have shown that 
not only does NLR independently predict short- 
and long-term mortality; it significantly improves 
prediction of short- and long-term mortality, when 
incorporated as a co-variable in standardized risk 
scores (e.g. TIMI-STEMI risk score). Multiple 
ACS studies now support the use of NLR as an 
admission biomarker, which can be used to de-
termine prognosis [25, 26]. NLR can be readily 
calculated at point of care, thereby facilitating 
short- and long-term risk prediction for STEMI 
patients, even prior to revascularization. Arbel et 
al. [27] found that increased NLR was associated 
with increased severity of CAD, thereby providing 
additive predictive value to conventional risk fac-
tors and commonly used biomarkers e.g. C-reactive 
protein and total white cell count. Similarly, in 
a large population based acute MI incident cohort, 
the absolute neutrophil count at presentation was 
strongly, positively, and independently associated 
with death/heart failure post-MI with an incremen-
tal discriminatory value for the absolute neutrophil 
count over traditional cardiac risk factors [28].
Female gender and low GFR has been shown in 
this study and others, to be independent predictors 
of mortality and MACE [23, 27, 28]. Our data was 
prospectively collected with NLR blood samples 
analyzed at admission, which is the most critical 
time point for clinicians to determine the choice 
of reperfusion therapy, based on the predicted 
interventional outcome of the presenting case. 
Pre-admission or initial presentation prognostic 
indices are of vital importance in the accurate triage 
of emergency room patients for STEMI revascu-
larization. They may even be more important for 
the long-term prognosis of all-cause mortality, than 
the immediate outcome of PCI [25]. For instance, 
the overwhelmingly poor short- and long-term 
predicted mortality of certain STEMI patients, 
might preclude invasive intervention, and mandate 
more conservative management strategies. Inte-
restingly, more complicated risk scoring systems 
that incorporate more comprehensive angiographic 
parameters and/or presentation hemodynamic va-
riables, do not necessarily improve the long-term 
prediction of all-cause mortality [26]. Furthermore, 
the clinical variables used in risk prediction models 
vary in predictive risk assessment capacity accor-
ding to the time point being considered post-MI 
[29, 30]. In this regard, we suggest that the NLR is 
robust in its consistent benefit for reliably predic-
ting both immediate, intermediate, and long-term 
mortality following revascularized STEMI.
Limitations of the study
Our study has several inherent limitations sin-
ce retrospective analyses are subject to selection 
bias. Moreover, the population studied was from 
a single tertiary care center. However, our study 
population demographics reveal a good mix of 
Hispanic, African American and Asian populations 
(51.6%) compared to the predominant Caucasian 
dominated populations studied in most major ACS 
clinical score derivation trials. While a single ba-
seline admission complete blood count sampling 
has the benefit of being readily available, serial 
sampling may potentially yield a better analytical 
time point. However, since the exact time to peak 
inflammatory response after STEMI remains un-
known, it is difficult to determine the most efficient 
collection time. Alternative concomitant etiologies 
for elevated NLR may have been present and not 
accounted for e.g. occult infection or malignancy. 
An NLR of 7.4 or greater at admission carried gre-
ater risk of adverse outcome in our study, although 
other studies have suggested differing NLR cut 
off points. A larger multi-center study with larger 
population size and diversity is warranted to best 
determine the future prognostic role of NLR, its 
best predictive cut off value, and sampling time.
Conclusions
NLR is a readily ascertainable, inexpensive, 
and reproducible biomarker for STEMI prognosis 
after PCI. It can be utilized as a robust stand-alone 
prognostic indicator for patients presenting with 
STEMI, even before eventual angiographic fin-
dings and outcomes are accounted for. When NLR 
is combined with standardized clinical mortality 
risk prediction scores, it markedly and significantly 
augments the predictive power of these scores.
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